The estimated Net Worth of Anne S Drapeau is at least $3.98 Milion dollars as of 16 March 2015. Anne Drapeau owns over 3,476 units of Vaxcyte stock worth over $3,982,539 and over the last 11 years Anne sold PCVX stock worth over $0.
Anne has made over 5 trades of the Vaxcyte stock since 2014, according to the Form 4 filled with the SEC. Most recently Anne exercised 3,476 units of PCVX stock worth $394,700 on 16 March 2015.
The largest trade Anne's ever made was exercising 33,658 units of Vaxcyte stock on 15 August 2014 worth over $734,754. On average, Anne trades about 5,889 units every 14 days since 2014. As of 16 March 2015 Anne still owns at least 35,073 units of Vaxcyte stock.
You can see the complete history of Anne Drapeau stock trades at the bottom of the page.
Anne's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... oraz Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: